Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incobotulinumtoxin-A for Diabetic Neuropathic Pain
NCT05623111Phase 2Recruiting
- Sponsor
- Rigshospitalet
- Start
- Aug 2023
- Primary completion
- May 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of botulinum toxin type A in diabetic neuropathy, sponsored by Rigshospitalet. Started Aug 2023; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT05623111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623111.